首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Development of a Sortase A-mediated Peptide-labeled Liposome Applicable to Drug-delivery Systems
【24h】

Development of a Sortase A-mediated Peptide-labeled Liposome Applicable to Drug-delivery Systems

机译:Sortase A介导的肽标记脂质体的开发适用于药物传递系统。

获取原文
获取原文并翻译 | 示例
       

摘要

Background/Aim: In order to develop an efficient drug-delivery system (DDS), a lipopeptide-loaded liposome that functions as a platform for the transpeptidase reaction mediated by sortase A (SrtA) was constructed and its stability, as well as cell-specific targeting were evaluated in the present study. Materials and Methods: Several lipopeptides possessing an acceptor peptide sequence (oligoglycine >= three residues) or donor peptide sequence (LPETG) for the SrtA-mediated reaction were chemically synthesized and then inserted into the liposome membrane composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol (DPPC-Chol-lipo) to obtain the lipopeptide-loaded liposomes. The transpeptidase reaction mediated by recombinant SrtA (His-Delta N59SrtA) was employed to modify the peptide moiety on the liposomal surface using a fluorescently-labeled substrate peptide corresponding to the species of each loaded lipopeptide. Furthermore, lung tumor-binding peptide (LTBP)-labeled liposomes, prepared by this transpeptidase reaction, were investigated for selective targeting to lung cancer cells in vitro. Results and Discussion: The His-Delta N59SrtA-mediated transpeptidation of fluorescently-labeled peptide on the lipopeptide-loaded DPPC-Chol-lipo was confirmed. The selective targeting of LTBP-labeled liposomes to the lung cancer cell line A549 was also observed in vitro. These results suggest that the labeling of acceptor or donor lipopeptide-loaded liposomes with the transpeptidase SrtA could be a useful method for developing a platform applicable to a cancer-targeting DDS.
机译:背景/目的:为了开发有效的药物递送系统(DDS),构建了负载脂肽的脂质体,该脂质体充当分选酶A(SrtA)介导的转肽酶反应的平台,并具有稳定性以及细胞在本研究中评估了特异性靶向。材料和方法:化学合成几种具有受体肽序列(寡甘氨酸> =三个残基)或供体肽序列(LPETG)的脂肽,用于SrtA介导的反应,然后插入由1,2-二棕榈酰-sn组成的脂质体膜中-甘油-3-磷酸胆碱(DPPC)和胆固醇(DPPC-Chol-lipo)来获得脂肽负载的脂质体。由重组SrtA(His-Delta N59SrtA)介导的转肽酶反应被用来修饰脂质体表面上的肽部分,使用的荧光标记底物肽对应于每种负载的脂肽的种类。此外,研究了通过这种转肽酶反应制备的肺肿瘤结合肽(LTBP)标记的脂质体在体外对肺癌细胞的选择性靶向。结果与讨论:证实了在脂质体负载的DPPC-Chol-lipo上,His-Delta N59SrtA介导的荧光标记肽的转肽作用。在体外也观察到LTBP标记的脂质体对肺癌细胞系A549的选择性靶向。这些结果表明,用转肽酶SrtA标记受体或供体脂肽的脂质体是开发适用于靶向癌症的DDS的平台的有用方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号